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Objective. To determine serum levels of B cell activating factor belonging to the tumor necrosis 
factor family (BAFF), a potent B cell survival factor, and clinical association in patients with 
systemic sclerosis (SSc).  
Methods. Serum BAFF levels from 83 SSc patients were examined by ELISA. For a longitudinal 
study, 131 sera from 21 SSc patients were analyzed. BAFF mRNA expression in the skin was 
quantified by real-time RT-PCR. BAFF receptor (BAFF-R) expression on CD19+ B cells was 
assessed by flow cytometry. IgG and IL-6 production by isolated B cells was examined by 
ELISA.  
Results. Serum BAFF levels were elevated in SSc patients compared to healthy controls and 
correlated positively with the extent of skin fibrosis. In a longitudinal study, 21 SSc patients were 
classified as follows: 7 patients with decreasing BAFF levels; 11 with unchanged levels; and 3 
with increasing levels. Decreasing BAFF levels were accompanied by regression of skin 
sclerosis, whereas increasing levels were associated with new onset or worsening of organ 
involvement. BAFF mRNA expression was up-regulated in the affected skin from early patients 
with diffuse cutaneous SSc. BAFF-R expression on B cells was increased in SSc patients relative 
to healthy controls. Furthermore, SSc B cells exhibited an enhanced ability to produce IgG and 
IL-6 by BAFF stimulation.  
Conclusion. These results suggest that BAFF and its signaling in B cells contribute to B cell 
abnormalities and disease development in SSc.  
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Systemic sclerosis (SSc) is a connective tissue disorder characterized by excessive 
fibrosis in the skin and various internal organs, with autoimmune background. A variety of 
immunological abnormalities of T and B lymphocytes have been detected in SSc (1). 
Autoantibodies are positive in over 90% of patients and these autoantibodies react to various 
intracellular components. The autoantibodies associated with SSc include anti-DNA 
topoisomerase I, anticentromere, anti-RNA polymerases, anti-U3RNP, and anti-Th/To antibodies 
(Abs) (2). Furthermore, hyper-γ−globulinemia and B-cell hyperactivity are detected in SSc 
patients (3, 4). A recent study demonstrated that SSc patients have distinct abnormalities of blood 
B lymphocyte compartments characterized by expanded naive B cells and activated memory B 
cells (5). In a tight-skin mouse, a genetic model of SSc, chronic B cell activation is critical not only 
for induction of autoantibodies, but also for the development of skin fibrosis (6). Although the 
pathogenesis of SSc remains unknown, B cell abnormalities characterized by autoantibody 
production and polyclonal B cell activation play an important role. 
B cell activating factor belonging to the tumor necrosis factor family (BAFF), also known 
as BLyS, TALL-1, and THANK, is a tumor necrosis factor (TNF) superfamily member 
(TNFSF13B) best known for its role in the survival and maturation of B cells (7). The BAFF 
gene encodes a putative type II transmembrane protein of 285 amino acids (8). A 152 amino acid 
form can also be shed from the membrane and is detectable in human serum (8-11). BAFF is 
produced by several cell types, including monocytes, macrophages, neutrophils, dendritic cells, 
and T lymphocytes (8, 12), and is a ligand for at least three TNF receptor superfamily (TNFRSF) 
members: B-cell maturation antigen (BCMA/TNFRSF17), transmembrane activator and 
calcium-modulator and cyclophilin ligand interactor (TACI/TNFRSF13B), and BAFF receptor 
(BAFF-R/BR3/TNFRSF13C) (13, 14). All three receptors are primarily expressed by B cells (7). 
Among them, BAFF-R plays the central role in the BAFF system (13). BAFF/BAFF receptor 
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family appears to span nearly all stages of B-lineage differentiation, ranging from the 
development, selection, and homeostasis of naive primary B cells to the maintenance of 
long-lived bone marrow plasma cells (15, 16). BAFF also exhibits a strong costimulatory 
function for B cell activation in vitro (8, 12). Furthermore, excess BAFF rescues self-reactive B 
cells from anergy, which may play a crucial role of autoimmune induction and development (17). 
Mice overexpressing BAFF exhibit elevated B cell numbers in spleen and lymph node and 
characteristics of autoimmune diseases, including spontaneous autoantibody production, 
immunoglobulin (Ig) deposits in the kidneys, and glomerulonephritis (18-20). Thus, mice 
overexpressing BAFF appear to show autoimmune phenotype similar to patients with systemic 
lupus erythematosus (SLE) (14, 20). 
In humans, previous reports have shown elevated serum BAFF levels in SLE, rheumatoid 
arthritis (RA), and Sjögren’s syndrome patients (9-11, 21). Furthermore, elevated serum BAFF 
levels correlated with titer of autoantibodies, such as anti-double-stranded DNA Ab, rheumatoid 
factor (RF), and anti-Ro/La Ab in these autoimmune disorders, respectively (9, 10, 22). Despite 
distinct B cell abnormalities in SSc, serum BAFF levels were not previously investigated in SSc. 
In this study, we examined serum BAFF levels and related these results to clinical features in 
SSc patients. In addition, we assessed relevance of BAFF to altered B cell function in SSc. The 
current study showed elevated serum BAFF levels, their correlation with skin fibrosis, increased 
BAFF-R expression on B cells, and enhanced B cell function by BAFF stimulation in SSc. The 
results of this study suggest that BAFF and its signaling in B cells contribute to B cell 
abnormalities and disease development in SSc. 
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 Patients and Methods 
 Patients. Serum samples were obtained from 83 Japanese patients with SSc (70 females 
and 13 males). All patients fulfilled the criteria for SSc proposed by the American College of 
Rheumatology (23). Their median (range) age was 53 (20-80) years and the median (range) 
disease duration was 2.3 (0.2-30) years. These patients were grouped according to the 
classification system proposed by LeRoy et al. (24): 45 patients (35 females and 10 males) had 
diffuse cutaneous SSc (dcSSc) and 38 patients (35 females and 3 males) had limited cutaneous 
SSc (lcSSc). Anti-topoisomerase I Abs were positive for 43 patients; anticentromere Abs for 32; 
and anti-RNA polymerases I/III Abs for 8. The disease duration was calculated from the time of 
the first clinical event (other than Raynaud’s phenomenon) that was a clear manifestation of SSc. 
The disease duration of patients with dcSSc and lcSSc was 2.0 (0.2-18) and 3.0 (0.3-30) years, 
respectively. At the first visit, 5 patients had been treated with low-dose steroids (prednisolone, 
5-20 mg/day) and 8 patients with low-dose D-penicillamine (100-300 mg/day). None of the SSc 
patients had received other immunosuppressive therapy, and had a recent history of infection or 
other inflammatory diseases. As disease control in this study, we also examined serum samples 
from 25 patients with SLE and dermatomyositis (DM) that fulfilled the American College of 
Rheumatology criteria (25) and Bohan and Peter criteria (26, 27), respectively. Age- and 
sex-matched 25 healthy Japanese individuals [21 females and 4 males; age, 52 (26-72) years] 
were used as healthy controls. In addition, to assess the variability of serum BAFF levels over 
the course of a day, we obtained sera sampled from 6 healthy Japanese individuals [2 females 
and 4 males; age, 35 (31-42) years] in the morning, the daytime, and the night. 
For a retrospective longitudinal study, we analyzed 131 serum samples from 21 patients 
with SSc (16 females and 5 males; 14 with dcSSc and 7 with lcSSc). Their median (range) age 
was 54 (20-68) years and the median (range) disease duration was 3.0 (0.2-10) years at the first 
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visit. The median (range) follow-up period was 6 (2-6) years after the first visit. At the first visit, 
2 patients were treated with low-dose steroids (prednisolone, 5-20 mg/day). During the follow-up, 
11 additional patients received low-dose steroids (prednisolone, 5-20 mg/day), while the 
remaining 8 patients did not receive oral steroids. In addition to steroid treatment, 2 patients were 
treated with low-dose D-penicillamine (100-300 mg/day) at the first visit. During the follow up, 
one additional received low-dose D-penicillamine (100-300 mg/day). One patient received 
steroid pulse therapy, followed by 40 mg/day of oral prednisolone for subacute deterioration of 
interstitial pneumonitis during the follow-up period. Fresh venous blood samples were 
centrifuged shortly after clot formation and all samples were stored at –70°C before use. The 
protocol was approved by the Kanazawa University Graduate School of Medical Science, and 
informed consent was obtained from all patients.  
Clinical assessment. Complete medical histories, physical examinations, and laboratory 
tests were conducted for all patients at their first visit, with limited evaluations during follow-up 
visits. Skin score was measured by scoring technique of the modified Rodnan total skin thickness 
score (modified Rodnan TSS) (28). Organ system involvement was defined as described 
previously (29, 30): lung = bibasilar fibrosis on chest radiography and high-resolution computed 
tomography; esophagus = hypomotility shown by barium radiography; joint = inflammatory 
polyarthralgias or arthritis; heart = pericarditis, congestive heart failure, or arrhythmias requiring 
treatment; kidney = malignant hypertension and rapidly progressive renal failure without any 
other explanation; and muscle = proximal muscle weakness and elevated serum creatine kinase. 
Pulmonary function test, including vital capacity (VC) and diffusion capacity for carbon 
monoxide (DLco), was also tested. When the DLco and VC were <75% and <80%, respectively, 
of the predicted normal values, they were considered to be abnormal.  
ELISA. Specific enzyme-linked immunosorbent assay (ELISA) kits were used for 
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measuring serum BAFF levels (R&D systems, Minneapolis, MN), according to the 
manufacturer’s protocol. Each sample was tested in duplicate. The detection limit of this assay 
was 3.38 pg/ml. To assess the interference of RF in this ELISA system, RF was removed by 
incubation with an IgG-coated latex suspension. This absorption of the RF activity did not affect 
BAFF concentrations by ELISA (data not shown). Furthermore, serum BAFF levels did not 
correlate with RF levels in serum samples from SSc patients (data not shown). Therefore, there 
was no interference of RF in this ELISA system. 
RNA isolation and real-time RT-PCR. Skin biopsy specimens were obtained from the 
forearm of 18 dcSSc patients [15 females and 3 males; median (range) age, 56 (26-71) years]. 
Ten of these patients were grouped into early dcSSc with disease duration of less than 3 years, 
while 8 patients were grouped into late dcSSc with disease duration of more than 6 years. None 
of the early dcSSc patients received therapy. All late dcSSc patients received low-dose steroids 
(prednisolone, 5-20 mg/day). Ten age- and sex-matched healthy Japanese individuals [7 females 
and 3 males; age, 48 (25-60) years] were used as healthy controls. In addition, we examined the 
skin from patients with hypertrophic scar [4 females and 2 males; age, 31 (23-40) years] as 
disease control of fibrotic skin disorders. All skin samples were snap-frozen in liquid nitrogen 
and stored at –80°C before use. Total RNA from skin was extracted using QIAGEN RNeasy spin 
columns (QIAGEN Ltd., Crawley, UK) and digested DNaseI (QIAGEN Ltd.) to remove 
chromosomal DNA in accordance with manufacturer’s protocols. Total RNA was reverse 
transcribed to cDNA using Reverse Transcription System with random hexamers (Promega, 
Madison, WI). We performed real-time quantitative RT-PCR using the TaqMan® system 
(Applied Biosystems, Foster City, CA). We obtained BAFF probe and primers from TaqMan® 
Gene Expression Assays (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used to normalize mRNA, and probe and primers were from Pre-Developed 
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TaqMan® Assay Reagents (Applied Biosystems). Real-time PCR was performed on an ABI 
Prism 7000 Sequence Detector (Applied Biosystems) according to the manufacture’s instructions. 
Relative expression of real-time PCR products was determined using the ∆∆CT technique 
(Applied Biosystems User Bulletin #2) as previously described (31). A comparative threshold 
cycle (CT) was used to determine gene expression relative to normal control (calibrator). We 
normalized each set of samples by housekeeping gene (GAPDH) using the formula of ∆CT = CT 
BAFF – CT GAPDH. One of the control samples was then chosen as a calibrator and relative mRNA 
levels were calculated by the expression 2-∆∆CT where ∆∆CT = ∆CT sample – ∆CT calibrator. Hence, 
BAFF mRNA levels were expressed as an n-fold difference relative to the calibrator. Each 
reaction was done in, at least, triplicate. 
Flow cytometric analysis. Blood samples were obtained from 15 SSc patients (12 females 
and 3 males; 10 with dcSSc and 5 with lcSSc). Their median (range) age was 35 (21-70) years 
and the median (range) disease duration was 2.1 (1-5) years at the first visit. Four of these SSc 
patients were treated with low-dose steroids (prednisolone, 5-20 mg/day). None of these SSc 
patients was treated with D-penicillamine or other immunosuppressive therapy. Ten age- and 
sex-matched healthy Japanese individuals [7 females and 3 males; age, 39 (25-52) years] were 
used as healthy controls. Two-color analysis was performed using phycoerythrin-conjugated 
anti-BAFF-R (BR3; eBioscience, San Diego, CA) and fluorescein isothiocyanate-conjugated 
anti-CD19 (B4; Beckman Coulter, Miami, FL) monoclonal antibodies (mAbs). For 
immunofluorescence staining, fresh heparinized whole blood samples were placed on ice 
immediately after collection. Blood samples (50 µl) were stained at 4°C using predetermined 
saturating concentrations of the test mAb for 20 minutes, as previously described (32). Blood 
erythrocytes were lysed after staining using the Whole Blood Immuno-Lyse kit as detailed by the 
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manufacturer (Beckman Coulter). Cells were analyzed on a FACScan flow cytometer (BD 
PharMingen).  
Production of cytokines and IgG by purified B cells. Peripheral blood B cells were 
obtained from 15 SSc patients and 10 healthy controls, the same subjects examined for flow 
cytometric analysis described above. Peripheral blood mononuclear cells (PBMCs) from whole 
blood were isolated by VACUTAINER® CPT (Becton Dickinson, Franklin Lakes, NJ). Then, B 
cells were isolated from PBMCs by B cell Isolation Kit II, human (Miltenyi Biotec, Bergisch 
Gladbach, Germany). Briefly, PBMCs (1 x 107) were incubated for 10 minutes with 
biotin-cojugated mAb mixtures containing mAb to CD2, CD14, CD16, CD36, CD43, and 
CD235a. B cells were then isolated by incubating anti-biotin magnetic beads. After the isolation, 
>95% of cells were CD19+ by flow cytometric analysis.  
Purified B cells (1 x 105) were cultured in RPMI1640 containing 10% heat-inactivated 
fetal calf serum (Gibco, Life Technologies, Paisley, UK) in 96-well flat-bottom plates (Becton 
Dickinson) with stimuli, at 37°C in a 5% CO2 humidified atmosphere. The cells were stimulated 
with 0.01% Staphylococcus aureus Cowan strain (SAC; Sigma St. Louis, MO) plus 1 µg/ml of 
recombinant human BAFF (Peprotech, London, UK) as previously described (8). B cells were 
cultured for 72 hours, and IL-6 and IL-10 concentrations in the culture medium were measured 
by ELISA, according to the manufacturer’s protocols (PharMingen, San Diego, CA). In addition, 
B cells were cultured for 8 days, and IgG concentrations in the culture medium were measured 
by ELISA (Bethyl Laboratories, Montgomery, TX). Each sample was done in triplicate.  
Statistical Analysis. Statistical analysis was performed using Mann-Whitney U test for 
comparison of values, Fisher's exact probability test for comparison of frequencies, and 
Bonferroni’s test for multiple comparisons. Spearman's rank correlation coefficient was used to 
examine the relationship between two continuous variables. P values less than 0.05 were 
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Serum BAFF levels in SSc. Serum BAFF levels were significantly higher in SSc patients 
with [1.26 (0.32-5.67) ng/ml] than healthy controls [0.78 (0.39-1.37), P<0.001; Figure 1]. 
Similarly, serum BAFF levels were significantly higher in patients with SLE [1.63 (0.56-5.52), 
P<0.0001] or DM [1.00 (0.21-4.38), P<0.01] than healthy controls. SLE patients had the highest 
serum BAFF levels. Concerning SSc subgroups, both dcSSc [1.30 (0.32-5.67)] and lcSSc [1.16 
(0.60-2.34)] patients exhibited increased BAFF levels compared to healthy controls (P<0.0005 
and P<0.0001, respectively). Furthermore, serum BAFF levels were significantly elevated in 
dcSSc patients relative to lcSSc patients (P<0.05). Since serum BAFF level may vary over short 
time periods, we assessed the variability of serum BAFF levels by measuring sera sampled 
several times over the course of a day in 6 healthy individuals. Serum BAFF levels were similar 
between samples obtained in the night [0.68 (0.52-0.82) ng/ml], those in the morning [0.69 
(0.49-0.85) ng/ml], and those in the daytime [0.69 (0.52-0.82) ng/ml]. Furthermore, all blood 
samples examined in this study were obtained in the morning or the daytime. Thus, the 
variability of serum BAFF levels over a course of a day appeared to have no significant effect on 
our results. 
Clinical correlation of serum BAFF levels in SSc. Clinical and laboratory parameters 
obtained at the first evaluation were compared between SSc patients with elevated serum BAFF 
levels and those with normal levels. Values higher than the mean + 2SD (1.245 ng/ml) of the 
control serum samples were considered to be elevated in this study. BAFF levels were elevated 
in 52% (43/83) of SSc patients with 56% (25/45) of dcSSc patients and 47% (18/38) of lcSSc 
patients. There was no significant difference in disease duration between patients with elevated 
BAFF levels and those with normal levels (Table 1). In addition, BAFF levels did not correlate 
with disease duration in dcSSc, lcSSc, and total SSc, respectively (data not shown). SSc Patients 
 12 
with elevated BAFF levels exhibited significantly higher modified Rodnan TSS than those with 
normal levels (P<0.01; Table 1). BAFF levels correlated positively with modified Rodnan TSS in 
SSc patients (P<0.005, r=0.415; Figure 2). SSc patients with elevated serum BAFF levels more 
frequently had decreased %VC (P<0.05), arthralgia/arthritis (P<0.05), myositis (P<0.05), and 
elevated erythrocyte sedimentation rates (ESR; P<0.05). Furthermore, BAFF levels correlated 
positively with ESR in SSc patients (P<0.05, r=0.434; Figure 2). The level of IgG was 
significantly increased in SSc patients with elevated BAFF levels compared with healthy 
controls (P<0.05; Table 1). The level of IgG was higher in SSc patients with elevated BAFF than 
in SSc patients without elevated BAFF, but the difference was not statistically significant. BAFF 
levels did not significantly correlate with anti-topoisomerase I or anticentromere Ab levels 
determined by ELISA (data not shown). To determine whether BAFF is simply serving as a 
marker for dcSSc or serving as a marker for the skin score in dcSSc (and other manifestations, 
such as pulmonary fibrosis and renal disease), clinical features were compared between dcSSc 
patients with serum elevated BAFF levels and those with normal levels. As a result, modified 
Rodnan TSS was significantly higher in dcSSc patients with elevated BAFF levels [22 (8-42)] 
than those with normal levels [16 (5-24), P<0.005]. By contrast, the frequency of lung 
involvement and renal disease in dcSSc patients with elevated BAFF levels were similar to that 
in dcSSc patients with normal levels (72% versus 60% and 4% versus 5%, respectively). Thus, 
elevated BAFF levels were generally associated with the severity of skin sclerosis and 
inflammation in SSc, rather than dcSSc. 
Longitudinal study of serum BAFF levels in SSc. To assess the changes in serum BAFF 
levels during the follow-up in 21 SSc patients (14 with dcSSc and 7 with lcSSc), the levels were 
studied for 6 years after the first visit (Figure 3). The changes in skin sclerosis during the 
follow-up period were assessed by modified Rodnan TSS (Figure 3). When the changes in BAFF 
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level showed more than a 50% increase or more than a 50% decrease at one or more time-points 
during the follow-up period compared with BAFF level at the first visit, the changes were 
defined as “increased” and “decreased”, respectively. Otherwise, the BAFF level was defined as 
“unchanged”. According to the criteria, 21 SSc patients were classified as follows: 7 (33%) 
patients with decreased BAFF levels; 11 (52%) with unchanged levels; and 3 (14%) with 
increased levels (Figure 3).  
All patients in the “decreased” group had dcSSc with the disease duration of 2.0 (0.2-3.0) 
years (Figure 3A). At the first visit, none of the patients was treated with oral steroids and one 
patient with 200 mg/day of D-penicillamine. During the follow-up, all patients received low-dose 
steroids (prednisolone, 5-20 mg/day) and one additional patient received 300 mg/day of 
D-penicillamine. High BAFF levels (over 2.0 ng/ml) at their first visit were significantly 
decreased after 1 year and remained decreased thereafter. Furthermore, in comparison with 
modified Rodnan TSS at the first visit, it was significantly decreased after 2 years (36% decrease, 
P<0.05), 4 years (45%, P<0.05), and 6 years (54%, P<0.05). Thus, the decreased change in 
serum BAFF levels was associated with the improvement of skin sclerosis in early dcSSc 
patients with high BAFF levels at their first visit.  
The “unchanged” group consisted of 4 patients with dcSSc and 7 with lcSSc (Figure 3B). 
The disease duration was 5.0 (1.0-10) years. At the first visit, one dcSSc patient was treated with 
10 mg/day of oral prednisolone. After the first visit, 3 additional dcSSc patients received 
low-dose steroids (prednisolone, 5-20 mg/day). None of the patients received low-dose 
D-penicillamine. In general, serum BAFF levels are moderate (range 1.0-2.0 ng/ml) at the first 
visit and remained stable throughout the follow-up period. Modified Rodnan TSS tended to be 
decreased as the disease progressed; however, there was no significant difference.  
 Serum BAFF levels increased during the observation period in 3 dcSSc patients with 
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moderate BAFF levels (range 1.0-2.0 ng/ml) at their first visit (Figure 3C). The disease duration 
was 1.5 (0.3-8) years. One patient exhibited subacute deterioration of interstitial pneumonitis 
after serum BAFF levels increased and then treatment with steroid pulse therapy was started, 
followed by 40 mg/day of oral prednisolone. One patient who had not been treated with steroids 
developed scleroderma renal crisis with cardiac tamponade, which resulted in death at the time 
point of the highest BAFF level. One patient who had been treated with 20 mg/day of oral 
prednisolone due to interstitial pneumonitis exhibited deterioration of secondary pulmonary 
hypertension, leading to death at the time point of the highest BAFF level. In general, decreased 
change in BAFF levels correlated with the improvement of skin sclerosis, while increased 
change in BAFF levels was associated with new onset or worsening of major organ involvement.  
BAFF mRNA expression in the dcSSc affected skin. To assess local BAFF expression in 
the affected skin from dcSSc patients, BAFF mRNA expression was quantified by real-time 
RT-PCR. The affected skin from early dcSSc patients showed fibrosis upon histological 
examination, while that from late dcSSc patients exhibited modest or absent skin fibrosis (data 
not shown). BAFF mRNA expression was significantly up-regulated in the affected skin from 
early dcSSc patients with disease duration of less than 3 years compared to that from late dcSSc 
patients with disease duration of more than 6 years, patients with hypertrophic scar, and normal 
controls (P<0.005, P<0.05, and P<0.001, respectively; Figure 4). BAFF mRNA expression in the 
skin from late dcSSc patients and patients with hypertrophic scar was similar to that from normal 
skin. Thus, local BAFF expression was up-regulated in fibrotic skin from early dcSSc patients. 
BAFF-R expression on SSc B cells. Recently, BAFF activity has been shown to correlate 
with BAFF-R expression patterns in vivo (33). Therefore, BAFF-R expression on blood B cells 
from SSc patients was assessed with flow cytometric analysis. BAFF-R expression levels on SSc 
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B cells [mean fluorescence intensity 81 ± 40 (mean ± SD)] were significantly higher than those 
found in healthy controls (43 ± 7, P<0.05; Figure 5A).  
Overproduction of IL-6 and IgG by SSc B cells. We investigated the role of BAFF in 
function of SSc B cells. B cells from SSc patients and healthy controls were stimulated with 
BAFF plus SAC, and culture supernatants were analyzed by ELISA to determine the amount of 
IL-6, IL-10, and IgG. SSc B cells stimulated with BAFF plus SAC produced 38% more IL-6 
than those from healthy controls (P<0.05; Figure 5B), while IL-10 production by stimulated SSc 
B cells was similar to that by B cells from healthy controls (Figure 5C). Furthermore, stimulated 
SSc B cells exhibited significantly enhanced IgG production by 35% relative to B cells from 
healthy controls (P<0.05; Figure 5D). Thus, SSc B cells in SSc patients had a significantly 
enhanced ability to produce IL-6 and IgG by BAFF stimulation.  
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Discussion 
This is the first report to reveal elevated serum BAFF levels in SSc. Elevated BAFF 
levels were associated with the severity of skin sclerosis. Our longitudinal study revealed that as 
serum BAFF levels decreased, skin sclerosis generally improved in early dcSSc patients with 
median disease duration of 2 years. A recent study using a tight-skin mouse has revealed that B 
cell activation status closely correlates with the development of skin sclerosis (6). Therefore, 
BAFF may be related to the development of skin sclerosis in SSc. In addition, 3 patients 
exhibited onset or worsening of major organ involvement parallel with an increase in serum 
BAFF levels. The results of this study suggest that serum BAFF levels reflect the disease 
severity and activity of SSc. However, we cannot exclude the possibility that changes in serum 
BAFF levels may be just reflecting responses to alterations in systemic inflammation, since 
various proinflammatory cytokines are known as potent inducers of BAFF (34). 
Since all SSc patients whose BAFF levels were decreasing during the follow-up received 
treatment with low-dose steroids of 5-20 mg/day, reduction in BAFF levels might be caused by 
steroid treatment. Although serum BAFF levels were reduced with high-dose steroids in SLE, 
steroid dose of less than 30 mg/day did not decrease serum BAFF levels in SLE (21). 
Furthermore, 2 of 3 SSc patients whose BAFF levels were increasing throughout the follow-up 
period also received treatment with low-dose steroids. These results suggest that low-dose 
steroids are not the only factor for decreasing BAFF levels in SSc. 
BAFF is an essential component of B cell homeostasis and a potent B cell survival factor 
associated with systemic autoimmune disease in animals (14, 18, 20). Previous studies have 
provided strong evidence that constitutive BAFF overproduction in mice leads not only to 
polyclonal hyper-γ−globulinemia, but also to spontaneous production of multiple antoantibodies, 
circulating immune complexes, and renal Ig deposits (14, 18, 20). In humans, elevated serum 
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BAFF levels have been found in SLE, RA, and Sjögren’s syndrome (9-11, 21). Furthermore, 
elevated serum BAFF levels correlated with titer of autoantibodies and hyper-γ−globulinemia in 
these autoimmune disorders (9, 10, 22). Similar to SLE, RA, and Sjögren’s syndrome, our results 
demonstrated that elevated BAFF levels were found in SSc and were associated with the increase 
in serum total IgG levels. Furthermore, elevated BAFF levels were associated with the severity 
of skin sclerosis. IL-6 and IgG by SSc B cells simulated with BAFF were enhanced. IL-6 induces 
concentration-dependent increases in the production of collagen and glycosaminoglycans from 
human dermal fibroblasts in vitro (35). Remarkably, blocking the IL-6 response by anti-IL-6 Ab 
results in a significant reduction in procollagen type I by culture dcSSc fibroblasts (36). Skin 
fibrosis in the tight-skin mice is improved with a parallel decrease in IL-6 production (6). In 
addition, serum IL-6 levels are elevated in patients with early dcSSc (37) and correlate with the 
extent of skin fibrosis (38). Therefore, augmented IL-6 production by SSc B cells stimulated 
with BAFF may be related to the development of fibrosis. 
Previous studies have suggested that SSc B cells are chronically activated since the 
frequency of B cells expressing activation markers, including HLA-DR and CD25, is increased 
in SSc (3, 39, 40). In addition, we have shown that B cells from SSc patients overexpress CD19 
by ~20% (32). CD 19 is a critical cell-surface signal transduction molecule on B cells that 
regulates basal signaling thresholds and accelerates signaling through B cell antigen receptor 
(41). Remarkably, transgenic mice with a similar increase in CD19 expression exhibit 
hyper-γ−globulinemia and produce characteristic autoantibodies with specificities similar to 
autoantibodies in human SSc (32). Furthermore, B cells from tight-skin mice display enhanced 
CD19 signaling with a chronically activated phenotype, hyper-γ−globulinemia, and spontaneous 
autoantibody production; these phenomena are completely eliminated by the loss of CD19 
expression on B cells (6). Furthermore, BAFF stimulation enhances CD19 expression and 
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increases the ability of B cell antigen receptor to phosphorylate CD19 (42). Thus, excess BAFF 
may accelerate B cell hyperactivity via overexpression and phosphorylation of CD19 and thereby 
contribute to B cell abnormalities in SSc. 
In RA patients, BAFF level in the synovial fluid greatly exceeds that in the blood (9). 
BAFF is also highly expressed in inflamed RA synovium and salivary glands of Sjögren’s 
syndrome (11). Similar to RA and Sjögren’s syndrome, our results showed that BAFF mRNA 
expression was up-regulated in the affected skin from early dcSSc patients. A recent study using 
DNA microarrays has revealed that genes characteristically expressed in B cells show 
differential expression between dcSSc and normal skin biopsies (43). Furthermore, analysis of 
lymphocyte population in dcSSc skin biopsies has demonstrated that B cell signature observed 
on the DNA microarrays is from CD20+ B cells (43). Therefore, our results suggest that the 
dysregulation of BAFF expression is related to the development of skin fibrosis via activation of 
infiltrating B cells into the affected skin. 
Since there are few established basic therapies for skin sclerosis and lung fibrosis in SSc, 
new therapeutic agents have been researched. Recently, BAFF have been shown to be a 
therapeutic target in SLE (44). Serum BAFF levels are increased and are correlated with 
autoantibody production in human SLE (21). Furthermore, inhibition of BAFF by TACI-Ig and 
BAFFR-Ig is successful in treating a murine model of SLE (14, 45). Moreover, treatment with 
BAFF antagonists, such as human anti-BAFF mAb, were already started in SLE patients and 
showed safety (46, 47). Our finding that elevated serum BAFF levels were associated with the 
disease severity and activity in SSc suggests that BAFF inhibition could be potential therapeutic 
targets of SSc as well as SLE. 
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Table 1. Clinical and laboratory data of patients with SSc showing elevated serum BAFF level.  
 SSc 
 
Elevated BAFF Normal BAFF 
(n = 43) (n = 40) 
Median (range) age at onset (yr) 52 (20-77) 55 (24-80) 
Sex (female/male) 34/9 36/4 
Median (range) disease duration (yr) 2.3 (0.2-27) 2.2 (0.5-30) 
Subtype of SSc   
  Diffuse cutaneous SSc  60% 50% 
  Limited cutaneous SSc  40% 50% 
Median (range) modified Rodnan TSS 18 (2-42)** 9 (2-24) 
Clinical features   
  Pitting scars 45% 39% 
  Contracture of phalanges 68% 39% 
  Diffuse pigmentation 60% 45% 
  Telangiectasia 43% 47% 
Organ involvement   
  Lung 48% 47% 
   Decreased %VC  40%* 18% 
   Decreased %DLco 78% 63% 
  Esophagus 50% 47% 
  Heart 13% 11% 
  Kidney 5% 3% 
  Joint  38%* 16% 
  Muscle  23%* 5% 
Laboratory findings   
  Anti-topoisomerase I Ab 53% 50% 
  Anticentromere Ab 30% 48% 
  Anti-RNA polymerases I/III Ab 16% 3% 
  Elevated ESR  48%* 29% 
  Elevated CRP 23% 16% 
  Median (range) IgG (µg/ml)   1543 (958-3320) *** 1493 (722-2890) 
  Median (range) IgA (µg/ml)     301 (98-769)       289 (128-645) 
  Median (range) IgM (µg/ml)     140 (59-829) 150 (59-445) 
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All the clinical and laboratory parameters and serum BAFF levels were obtained at the first 
evaluation.  
*P<0.05 or **P<0.01 vs. SSc patients with normal BAFF levels 
***P<0.05 vs. serum total IgG levels [1320 (855-2250)] of healthy controls (n = 25).  




Figure 1. Serum BAFF levels in patients with autoimmune diseases at the first evaluation. BAFF 
levels were determined by a specific ELISA in serum samples from patients with diffuse 
cutaneous SSc (dcSSc), limited cutaneous SSc (lcSSc), systemic lupus erythematosus (SLE), or 
dermatomyositis (DM) and from healthy controls (Control). The dashed lines indicate the cut-off 
value (mean + 2SD of the control samples). The lines inside the boxes indicate the median; the 
outer borders of the boxes indicate 25th and 75th percentiles; the bars extending from the boxes 
indicate the 10th and 90th percentiles. 
 
Figure 2. The correlation of serum BAFF levels against modified Rodnan TSS and erythrocyte 
sedimentation rates (ESR) in patients with SSc at the first evaluation. Serum BAFF levels were 
determined by a specific ELISA.  
 
Figure 3. Serial changes in serum BAFF levels and modified Rodnan TSS during the follow-up 
period. In a longitudinal study, 131 serum samples from 21 patients with SSc (14 with dcSSc and 
7 with lcSSc) were analysed. SSc patients were classified into 3 groups: (A) patients whose 
BAFF levels decreased by more than 50% at one or more time-points, (B) patients whose BAFF 
levels changed by less than 50%, and (C) patients whose BAFF levels increased by more than 
50%. Top, serum BAFF levels were determined by a specific ELISA. The dashed lines indicate 
the cut-off value (mean + 2SD of the control samples). *P<0.005 vs. serum BAFF levels at the 
first visit. Bottom, the extent of skin sclerosis was measured by modified Rodnan TSS at the first 
visit and after 2, 4, and 6 years. Data are shown as the median (range). **P<0.05 vs. modified 
Rodnan TSS at the first visit.  
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Figure 4. BAFF mRNA expression in the affected skin of dcSSc. BAFF mRNA expression was 
quantified by real-time RT-PCR in the skin from early dcSSc patients with disease duration of 
less than 3 years (early dcSSc), late dcSSc patients with disease duration of more than 6 years 
(late dcSSc), patients with hypertrophic scar, and healthy controls (Control). The affected skin 
from early dcSSc patients showed fibrosis by histological examination, while that from late 
dcSSc patients exhibited modest or absent skin fibrosis (data not shown). BAFF mRNA 
expression relative to a calibrator, one of the control samples, was expressed as 2-∆∆CT (fold) and 
shown as a dot. The lines inside the boxes indicate the median; the outer borders of the boxes 
indicate 25th and 75th percentiles; the bars extending from the boxes indicate the 10th and 90th 
percentiles. 
 
Figure 5. Representative expression of BAFF-R on CD19+ B cells, and production of cytokines 
and IgG by peripheral blood B cells. Blood samples were obtained from 15 SSc patients and 5 
healthy controls (Control). BAFF-R expression was assessed by 2-color immunofluorescence 
with flow cytometric analysis (A). The horizontal dashed lines are provided for reference. For 
production of cytokines and IgG, purified B cells (1 x 105) from blood samples were stimulated 
with either medium alone or recombinant human BAFF plus Staphylococcus aureus Cowan 
strain (SAC). Culture supernatants were analyzed by ELISA to determine the amount of IL-6 (B), 
IL-10 (C), and IgG (D). 
 





